Lupus & Connective Tissue Diseases
From the Journals
First prospective study finds pregnancies with Sjögren’s to be largely safe
There was no difference in risk of adverse pregnancy outcomes between women with Sjögren’s and the control group, but these negative outcomes were...
Conference Coverage
Investigational lupus drug cenerimod moves to phase 3 studies after equivocal phase 2 results
Novel S1P1 receptor modulator cenerimod shows impact on disease activity in lupus, with more pronounced benefits in those with more severe disease...
Conference Coverage
Severe hydroxychloroquine nonadherence linked to worse SLE outcomes
Severe nonadherence to hydroxychloroquine in patients with lupus is associated with an increased risk of flare, organ damage, and mortality within...
Latest News
Lupus landmark study aims for personalized medicine goals
The Lupus Landmark Study was designed as part of the Lupus Nexus, a combination registry, biorepository, and data portal.
Conference Coverage
Early remission in lupus nephritis can still progress to advanced CKD
Patients with lupus nephritis who achieve complete remission within 1 year of starting treatment can still progress to advanced chronic kidney...
Conference Coverage
Biomarkers for measuring lupus nephritis treatment response gain ground
A panel of protein biomarkers in urine could achieve better identification of lupus nephritis patients who are likely to respond to treatment.
From the Journals
Cutaneous vasculitis curtails quality of life
Survey respondents described a generally poor health-related quality of life that was detailed as more severe with a skin-specific instrument than...
From the Journals
IVIG shows no impact on VTE risk in dermatomyositis patients
The rate of venous thromboembolism did not increase in dermatomyositis patients treated with intravenous immunoglobulin, compared with those not...
Conference Coverage
Low disease state for childhood lupus approaches validation
A new childhood version of the Lupus Low Disease Activity State has been purposefully developed to align with the criteria already used for adults...
From the Journals
Study shifts burden of IgG4-related disease to women
First population-based U.S. analysis establishes “key benchmarks” for immune-mediated condition initially described in 2001.
News from the FDA/CDC
FDA fast tracks potential CAR T-cell therapy for lupus
The cellular therapy depletes CD19-positive B cells with the goal of ‘‘resetting’’ the immune system to achieve durable remission.